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cascade, such as endothelial cell proliferation, migration, survival and 
capillary formation (1).
Vandetanib (ZD6474, Zactima) is a novel anilinoquinazoline which 
has shown activity as a potent and reversible inhibitor of VEGFR-2 
tyrosine kinase. It is a small molecule with good oral bioavailability 
and constant plasma drug levels. 
Furthermore, vandetanib also inhibits epidermal growth factor receptor 
tyrosine kinase activity combining activity against neoangiogenesis and 
signal transduction pathway (2).
Vandetanib has shown inhibition of tumor cell growth in a broad range 
of preclinical models including lung cancer xenografts after oral ad-
ministration with an acceptable preclinical toxicology proﬁle.
It was possible to demonstrate inhibition by vandetanib of EGF-stumu-
lated cell proliferation and inhibition of both VEGFR and EGFR tyro-
sine kinase in vitro, and preclinical models have shown activity against 
NSCLC xenografts (3). 
Vandetanib (ZACTIMA™; ZD6474) is a once-daily oral anticancer drug 
at the moment in phase III clinical development in a broad population of 
patients with advanced NSCLC. Vandetanib targets clinically validated 
signaling pathways in NSCLC by inhibiting VEGFR-dependent tumor 
angiogenesis and EGFR-dependent tumor growth and survival. Vande-
tanib also inhibits RET kinase activity, which is an important growth 
driver in certain types of thyroid cancer. 
Phase I evaluation in patients with advanced solid tumors showed 
vandetanib was generally well tolerated at daily oral doses of ≤300 mg. 
Common adverse events included rash, diarrhea and asymptomatic QTc 
prolongation, all of which were controlled by standard management. A 
series of randomized, double-blind Phase II studies have investigated the 
efﬁcacy of vandetanib in NSCLC, both as monotherapy and in com-
bination with certain chemotherapies. A two-part study (6474IL0003) 
compared vandetanib 300 mg with geﬁtinib (IRESSA™; 250 mg) in 
2nd/3rd-line NSCLC; in part B, eligible patients had the option to switch 
to the alternative treatment. The study achieved its primary efﬁcacy 
objective: median progression-free survival (PFS) in part A was 11 
weeks for vandetanib versus 8 weeks for geﬁtinib (hazard ratio = 0.69, 
95% CI = 0.50-0.96; 1-sided P = 0.013). In 2nd-line NSCLC, vandetanib 
(100 or 300 mg) or placebo was assessed in combination with docetaxel 
(6474IL0006). This study also achieved its primary objective, with 
vandetanib 100 mg + docetaxel demonstrating a signiﬁcant prolongation 
of PFS versus docetaxel alone (hazard ratio =0.64, 95% CI = 0.38-
1.05; 1-sided P = 0.037). In 1st-line NSCLC, vandetanib (300 mg/day) 
± carboplatin and paclitaxel (CP) was compared with CP + placebo 
(6474IL0007). The primary objective was met, with vandetanib + CP 
prolonging PFS versus CP alone (hazard ratio = 0.76, 95% CI = 0.50-
1.15; 1-sided P = 0.098): median PFS was 24 weeks (vandetanib + CP) 
and 23 weeks (CP). The vandetanib monotherapy arm was stopped early 
after a planned interim PFS analysis met the criterion for discontinuation 
(hazard ratio >1.33 versus CP). In all three studies, no overall survival 
beneﬁt with vandetanib was seen. However, overall survival was a sec-
ondary endpoint in these studies and the effect of vandetanib on survival 
is potentially confounded by the impact of post-progression therapies.
The positive outcomes from these phase II studies have led to the 
initiation of phase III evaluation of vandetanib in a broad population 
of patients with advanced NSCLC, including squamous and non-squa-
mous cell histology. There are four phase III trials in NSCLC currently 
recruiting patients: vandetanib 300 mg versus placebo in patients previ-
ously treated with anti-EGFR therapy (6474IL0044); vandetanib 300 
mg versus erlotinib in refractory NSCLC (6474IL0057); vandetanib 
100 mg + docetaxel versus placebo + docetaxel in 2nd-line NSCLC 
(6474IL0032); and vandetanib 100 mg + pemetrexed versus placebo + 
pemetrexed in 2nd-line NSCLC (6474IL0036). 
A randomized phase III trial comparing carboplatin paclitaxel and van-
detanib vs the same chemotherapy alone, has been recently completed 
in 300 patients.
Clinical development is also ongoing in other tumor types, including 
hereditary medullary thyroid cancer, where encouraging antitumor 
activity has been observed.
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Introduction
To date, the glucose analogue 18FDG still is the best PET tracer for 
staging of lung cancer. Experiments with thymidine-analogues, choline 
etc. have not revealed diagnostic superiority in terms of TNM staging. 
Moreover, the conceptually present biological (i.e. prognostic) value of 
tracers like 18FLT has not yet been elucidated. 
At the crossroads of tomographic imaging and intervention, the 
introduction of PET-CT and the increased application of non-surgical 
therapeutic modalities are the main developments in the past decade. 
PET(-CT) and staging
The diagnostic accuracy of PET needs to be stratiﬁed for nodal size at 
CT [1]. In meta-analysis the pooled sensitivity of PET to identify ≥N2 
stage in patients with non-enlarged nodes, was 0.75 (95%CI: 0.59-
0.87); in combination with pre-test probability of N2 in this situation 
[2], it is predicted that the negative predictive value of PET is about 
94%. Hence, even if invasive preoperative staging procedures would 
have a sensitivity of 100% (which is clearly not the case), at least 16 
invasive procedures would be required to identify a single patient with 
N2 disease. More recent studies conﬁrm that the yield of invasive 
staging procedures in patients with normal-sized and FDG-PET nega-
tive nodes is indeed extremely low [3]. In the meta-analysis of Gould 
et al, the sensitivity of PET in patients with enlarged nodes was 0.91 
(95%CI .79-.96). It is likely that this 16% lower sensitivity of PET (vs. 
non-enlarged nodes) is caused by partial volume effects with smaller 
tumor deposits (the typical post-reconstruction resolution of PET being 
about 5-7 mm). Above the centimeter limit, these effects are much less 
likely to affect diagnostic performance. The prevalence of malignancy 
in mediastinal nodes [4] with 10-15mm short axis diameters is 0.29 
(95%CI 0.23-0.36), vs. 0.68 (95%CI 0.52-0.81) for nodes of 16-20 
mm (i.e. similar to even larger nodes). Reasoning that partial volume 
effects are irrelevant with deposits > 10 mm, one can predict that the 
post-test probability of N2 disease in patients with 10-15mm nodes and 
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a negative PET scan is about 5%. Combined with a realistic sensitivity 
of mediastinoscopy of about 85%, we predicted that 25 patients need 
to undergo invasive staging in order to identify a single patient with N2 
disease. In a sensitivity analysis (dropping PET sensitivity and speciﬁc-
ity for this subset to 0.85 and 0.70, respectively), we found that these 
data are robust With nodes >15mm short axis diameter, the post-test 
probability of N2 disease is 0.21, suggesting that invasive evaluation 
is indicated in patients with such nodes at CT without positive 18FDG 
signal. Since 18FDG is not a tumor-speciﬁc agent, clinically decisive 
PET-positive lesions need to be conﬁrmed except in cases of widely 
disseminated extrathoracic tumor spread.
PET reading
Visual detection of ‘hot spots’ is the mainstay of mediastinal PET read-
ings. PET allows for very accurate signal quantiﬁcation. In the clinical 
setting, one uses the standardized uptake value (SUV), which basically 
is the ratio of measured activity in the tumor and the injected 18FDG 
dose. Because SUV can be readily obtained from whole body scans, it 
is the most widely applied method. The aim of adding quantiﬁcation 
to PET reading systems would be to improve speciﬁcity and perhaps 
reduce observer variation. Even though there is some evidence to sup-
port this notion [5] there is no generally accepted SUV cut-off (and due 
to the abovementioned partial volume effects it is unlikely that there is 
one). Since prevailing PET methods are heterogeneous meta-analysis 
is impossible. Several initiatives are underway to promote interinstitute 
calibration and standardization [6,7]. Functional imaging with PET 
involves biology and physics, and as such clearly puts higher demands 
on its users than we were used to in anatomical imaging: in order to 
obtain generally applicable data (e.g. SUV numbers) the full trajectory 
of patient preparation, image acquisition -, - reconstruction procedures 
and data-analysis need to be covered, and this is not trivial. Alterna-
tively, use of PET-CT rather than visual co reading of PET and CT adds 
speciﬁcity by identifying aspeciﬁc non-nodal uptake. 
Requirements for rational use of mediastinal PET readings 
1. the primary tumor needs to be 18FDG avid, since PET-detection of 
malignant tissue depends on contrast between uptake in target vs. back-
ground. Broncho-alveolar cancer cells can lack GLUT-1 transporters 
rendering the PET signal negative. On average, squamous cell cancer 
tends to have somewhat higher 18FDG uptake than adenocarcinoma, 
but in meta-analyses no clear difference in PET accuracy was reported. 
Assessment of a lower level 18FDG avidity relies upon the nuclear 
medicine physician’s judgment rather than upon a speciﬁed level of 
avidity (SUV) - for the same reasons as outlined before. Fortunately, 
this visual assessment has a low observer variation [8]. Therefore, with 
high clinicopathological suspicion of NSCLC but low 18FDG uptake in 
the primary process, a negative mediastinal reading should not guide 
clinical management. 
2. nodal stations directly adjacent to the primary tumor are likely not to 
be recognized at PET but remain hidden in the activity of the primary 
tumor. Note that most PET acquisitions are obtained during shallow 
breathing, unlike diagnostic CT scans; fusion of low-dose CT scans 
and PET (as customary with PET-CT) accounts for the potential effect 
of tumor shift during deep inspiration. The nuclear medicine physician 
should report which stations are subject to this potential problem.
3.similarly, spatial resolution limitations reduce anatomical conﬁdence 
of PET readings when trying to separate N1 and adjacent N2 stations. 
PET(-CT) and restaging
Several studies have investigated the diagnostic accuracy of PET to 
restage the mediastinum after induction therapy for locally advanced 
NSCLC. The results are clearly more heterogeneous than in the upfront 
staging situation. Among the potential effect modiﬁers one needs 
to consider the included patient spectra, the quality of the reference 
test (gold standard), type of induction therapy (chemo- and/or radio-
therapy), timing of PET vs. the intervention, PET vs. PET-CT, and PET 
classiﬁcation systems and - interpretation criteria. Obviously, once the 
diagnostic accuracy of PET to provide mediastinal mapping is clariﬁed, 
these data need to be ﬁtted into diagnostic and management algorithms. 
Preferably, research in either domain should be ‘in sync’ to prevent that 
diagnostic procedures keep pace with therapeutic developments. With 
the transition from induction chemotherapy to chemoradiation, this was 
clearly not the case. The standardization momentum in the PET com-
munity may be an important vehicle to allow for such joint efforts. 
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How to stage the mediastinum: mediastinoscopy
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Lung cancer more commonly spreads to the mediastinum than to other 
anatomic sites requiring thorough evaluation of the mediastinum in 
cases where there is no other evidence of metastases. The decision to 
treat for multimodality therapy hinges on the. An unanswered question 
is whether pre- versus post-operative chemotherapy provides better 
survival. Though, preoperative treatment allows for higher chemothera-
peutic drug delivery and more delivery to the loco-regional area of the 
primary tumor. By identifying those patients less likely to beneﬁt from 
surgical resection, such as contralateral and/or multinodal station/gross 
tumor involvement, unnecessary or “futile” thoracotomies should be 
minimized. Previously estimated to be as high as 30-40% now appear 
to be in the 5 to 10% range given the availability of high-resolution 
computed and positron emission tomographies (CT, PET, PET/CT) and 
even lower with a thoroughly pathologically-staged mediastinum. To 
highlight the importance of mediastinal lung cancer involvement, the 
American Joint Committee for Cancer Staging and Results Reporting 
and the American Thoracic Society adopted the Naruke staging map 
by provide systematic information on the prognosis of lung cancer 
patients. , Each region is numbered in the mediastinum and hilar, as it 
relates to the trachea, the main stem bronchi and the great vessels. The 
goals of mediastinoscopy are to better understand the biology of the 
patient’s disease. It allows selection of those patients who are at risk 
for earlier recurrence and poorer lung cancer survival and reduces the 
likelihood for a futile thoracotomy.
Mediastinoscopy is the “gold standard” method for assessing lung 
cancer mediastinal involvement and provides a minimally-invasive 
means of evaluating the mediastinal lymph nodes for the presence and 
degree of metastatic involvement, including microscopic, gross and 
trans-capsular involvement and “matted” of nodes; as well as direct 
extension of the primary tumor into the mediastinal pleura and into 
